Living mapping and living systematic review of Covid-19 studies

Studies registered

4711

Registered studies

1525

Randomized Trials (excluding Traditional Chinese Medicine trials)
851 RCTs recruiting

Results

34132

Records screened

Randomized Controlled trials

Non-randomized studies

227

Observational studies

Over the past week we have screened 1236 records:

We have identified and included three RCTs were included, their results are assessed and available on our website. 1) a study evaluating Intravenous Immunoglobulin (IVIG) to standard of care, 2) a study evaluating the prophylactic use of Hydroxychloroquine as comparted to standard of care 3) a study evaluating Hydroxychloroquine with or without Azithromycin

Two RCTs are included and pending additional information from authors for data extraction:1) evaluating Methylprednisolone and 2) a study evaluating the safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19

Two vaccine trials are under extraction and risk of bias assessment 1) Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older and 2) safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial)

Five eligible non-randomized studies are currently being extracted: 3 on corticosteroids and 1 on different treatments (anticoagulation steroids, antivirals, antibiotics and immunomodulators).

15 other observational studies have been added to the list on our website.

We also received some supplemental information from authors of previously included RCTs and the data are included and updated in our systematic review.

We updated the search on ICTRP on July 28, 2020 and identified 77 new trials.

To receive updates on our project and research findings, please subscribe to our weekly digest, we will share with you new RCT results and other interesting news.

Our main activities

We are performing a living mapping of ongoing research followed by a living network meta-analysis of study results as soon as they are available.

We are searching and extracting data from RCTs registered in ICTRP once a week (the WHO updates its registry every Wednesday).
We are updating the living mapping and evidence synthesis on our website once a week (every Friday).
A living mapping of studies registered is now available: it is possible to filter studies by type of pharmacological treatment, registration date, study aim, severity scale. An interactive map showing the clinical trials per country is also available. This data visualization was developed by a team from the LIRIS laboratory (CNRS/École Centrale de Lyon) in the context of a large collaboration with the CNRS. Several other teams from CNRS have offered their help for this project to contribute to the fight against Covid-19. As a result, more graphs and tables are currently being developed and will be soon available on our website.
We are screening electronic databases (PubMed/Chinarxiv and MedRxiv) every day to identify results of RCTs and non-randomized-studies.
We are collecting data from all RCTs identified. The main characteristics of trials, including a complete description of the assessment of each risk of bias domain with support for judgement and forest plots are available here. The Evidence profile and Summary of Findings (SoF) tables for most of the comparisons are also available online and the missing ones are currently being designed.
We are contacting all investigators of ongoing trials to obtain the trial protocol and results as soon as available.
Several databases of the reference list for modeling studies, observational studies, RCTs and non-RCT studies and studies we excluded from our systematic review are available online . Users of datasets published by the Covid-NMA project are required to acknowledge the source with an appropriate citation. We recommend using the following format: Authors. (Year). Dataset title [Data set]. Repository. DOI

Our process is summarized in this figure. For more information on our methods see our protocol here.

This study received funding from the Agence Nationale de la Recherche (ANR).

We encourage all investigators of Randomized Controlled Trials to contact us as soon as they have results available.